D. Boral Capital Reiterates “Buy” Rating for NRx Pharmaceuticals (NASDAQ:NRXP)

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating reiterated by D. Boral Capital in a note issued to investors on Monday,Benzinga reports. They currently have a $34.00 target price on the stock.

A number of other brokerages have also recently issued reports on NRXP. Weiss Ratings reiterated a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research report on Wednesday, October 8th. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of NRx Pharmaceuticals in a report on Thursday, October 16th. Ascendiant Capital Markets boosted their target price on shares of NRx Pharmaceuticals from $46.00 to $47.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. BTIG Research reiterated a “buy” rating on shares of NRx Pharmaceuticals in a research report on Monday, August 25th. Finally, Zacks Research upgraded shares of NRx Pharmaceuticals to a “hold” rating in a report on Wednesday, September 10th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, NRx Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $34.75.

NRx Pharmaceuticals Stock Up 4.1%

Shares of NASDAQ:NRXP traded up $0.10 on Monday, reaching $2.55. The company had a trading volume of 177,711 shares, compared to its average volume of 493,520. The stock has a 50-day moving average price of $3.02 and a 200 day moving average price of $2.87. The stock has a market capitalization of $50.52 million, a P/E ratio of -1.14 and a beta of 1.76. NRx Pharmaceuticals has a twelve month low of $1.12 and a twelve month high of $6.01.

NRx Pharmaceuticals (NASDAQ:NRXP) last released its earnings results on Monday, August 18th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.67). On average, sell-side analysts predict that NRx Pharmaceuticals will post -1.75 earnings per share for the current fiscal year.

Institutional Trading of NRx Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Ethos Financial Group LLC acquired a new stake in shares of NRx Pharmaceuticals during the 3rd quarter valued at $39,000. One Wealth Management Investment & Advisory Services LLC raised its position in NRx Pharmaceuticals by 86.1% in the third quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company’s stock valued at $92,000 after purchasing an additional 12,950 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of NRx Pharmaceuticals by 27.9% during the second quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock valued at $562,000 after purchasing an additional 37,598 shares in the last quarter. AdvisorShares Investments LLC increased its stake in shares of NRx Pharmaceuticals by 29.7% in the third quarter. AdvisorShares Investments LLC now owns 342,136 shares of the company’s stock valued at $1,129,000 after buying an additional 78,339 shares during the period. Finally, Vanguard Group Inc. raised its holdings in NRx Pharmaceuticals by 18.3% in the 3rd quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock valued at $1,765,000 after buying an additional 82,781 shares during the last quarter. Institutional investors own 4.27% of the company’s stock.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.